Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Antiviral Res. 2019 Aug 1;170:104573. doi: 10.1016/j.antiviral.2019.104573

Fig 2. Clinical outcome of heterologous CCHFV challenge following VRP vaccination.

Fig 2.

(A) Weight change in mice following VRP vaccination (1 × 105 TCID50). (B) Survival in mice challenged SC with a target dose of 100 TCID50 of indicated CCHFV strains 28 days after VRP vaccination. (C) Post-challenge weight change and water intake. (D) AAU of anti-NP IgM or IgG, and anti-Gc IgG in plasma collected when mice reached end-point criteria (open symbols) or at completion of the study (closed symbols; 21 days post challenge). Time post-infection of sampling, outcome, and corresponding antibody levels for individual mice is provided in Supplementary Table 3.